CHICAGO --(BUSINESS WIRE)--Sep. 12, 2024-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the beta launch of a patient-facing app, olivia , an AI-enabled personal health concierge to empower individuals
The strategic collaboration will leverage Tempus’ large multimodal datasets to enhance BioNTech’s next-generation oncology pipeline CHICAGO --(BUSINESS WIRE)--Sep. 4, 2024-- Tempus AI, Inc. (NASDAQ: TEM, “Tempus”), a technology company leading the adoption of AI to advance precision medicine and
CHICAGO --(BUSINESS WIRE)--Aug. 28, 2024-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4th , held in New York,
CHICAGO --(BUSINESS WIRE)--Aug. 8, 2024-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the validation study of its human leukocyte antigen (HLA) loss of heterozygosity (LOH) investigational assay
CHICAGO --(BUSINESS WIRE)--Aug. 6, 2024-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter that ended June 30, 2024 , and provided recent business highlights.
New RNA-based algorithm is now available with the xR assay CHICAGO --(BUSINESS WIRE)--Aug. 1, 2024-- Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced the launch of a new program specifically geared towards using algorithms to surface
CHICAGO --(BUSINESS WIRE)--Jul. 30, 2024-- Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, announced an expanded collaboration with Remix Therapeutics, a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing
CHICAGO --(BUSINESS WIRE)--Jul. 17, 2024-- Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter on Tuesday, August 6, 2024 . The company will hold the second quarter 2024 earnings
Available Today for Life Science Research Use Only CHICAGO --(BUSINESS WIRE)--Jul. 16, 2024-- Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that its multimodal immune profile score (IPS) algorithmic test is now available for research use
CHICAGO --(BUSINESS WIRE)--Jul. 10, 2024-- Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, has reached a research milestone of over 500 research publications. In the last eight years, Tempus has invested in rigorous scientific research to validate its
